
Biocompatibility in a wearable medical device is the ability of the finished device to perform its intended function without causing unacceptable biological harm in the specific way it is used. It is not an inherent property of a material, and it cannot be guaranteed by a material label or a single test result. A hydrogel that is well tolerated in a 24-hour patch may behave very differently in a seven-day device worn on sweaty, mobile skin. For this reason, biocompatibility must always be assessed in relation to the device’s intended use, contact type, contact duration, and the way it is manufactured.
For engineers developing wearable medical devices such as ECG patches, biosensors, or flexible electrodes, this has practical consequences. Material selection, processing, and the regulatory pathway are shaped by biological evaluation from the earliest design stages, not at the end of development. This guide is a broad overview of biological evaluation for wearable devices: the regulatory frameworks, the main biological concerns, how skin-contact materials compare, the manufacturing factors that can change biological risk, and how to build biocompatibility thinking into development. It deliberately links to more specialized Screentec articles rather than repeating their detail.
Biological evaluation is a risk-based process
The primary international standard for the biological evaluation of medical devices is the ISO 10993 series. Its foundation, ISO 10993-1, frames biological evaluation as a risk management process within the device’s overall risk management activities. The current edition, ISO 10993-1:2025, reinforces this approach and aligns biological evaluation more closely with ISO 14971 risk management. In practice, the manufacturer identifies biological hazards, considers the materials and processing, evaluates what exposure is realistic, and then decides what evidence is needed to show that residual biological risk is acceptable.
This means there is no universal checklist that applies identically to every wearable. The evidence needed for a short-term, intact-skin device differs from that needed for a device worn for days, and a device made from materials with a long history of safe use in comparable applications may need less new testing than one using novel formulations. Testing is one source of evidence among several, alongside existing safety data, chemical characterization, and toxicological risk assessment.
Regulators approach this framework in their own ways. In the US, the FDA publishes guidance on the use of ISO 10993-1 for biocompatibility assessment of medical devices, and its expectations apply within the broader premarket submission process. In the EU, the Medical Device Regulation (MDR 2017/745) requires biological safety to be addressed in the technical documentation supporting CE marking. Developers should consult the current versions of the standards and the relevant regulator guidance for their device and market, and should not assume that an approach accepted for one product will transfer unchanged to another.
What determines the evaluation: contact, duration, and exposure
ISO 10993-1 categorizes devices by the nature of body contact and the duration of that contact. For wearable devices, the most relevant categories involve surface contact with intact skin, although devices applied to breached or compromised skin, or in proximity to mucosal surfaces, fall into different categories with different expectations. Contact duration is usually grouped into limited (up to 24 hours), prolonged (more than 24 hours up to 30 days), and long-term (more than 30 days). Because repeated or cumulative use can count toward total contact duration, a single-use patch applied daily over several weeks may need to be considered differently from its single-application duration alone.
Beyond these categories, several factors determine the evidence a given wearable actually needs:
- Material formulation: the composition of adhesives, hydrogels, inks, films, and additives, including residual monomers, plasticizers, and processing aids.
- Processing: printing, curing, lamination, cleaning, and sterilization steps that can add, remove, or transform substances in the finished product.
- Exposure: which components actually touch the skin, how much surface area is involved, and what can migrate out under real wear conditions.
- Finished-device considerations: interactions between materials once assembled, packaged, and, where applicable, sterilized.
Biological endpoints relevant to skin-contact wearables
ISO 10993 addresses biological endpoints through its individual parts. The endpoints most often discussed for skin-contact wearables include the following, although which of them apply to a given device is a decision made through the biological evaluation plan, not a fixed rule.
- Cytotoxicity (ISO 10993-5): whether extracts or contact with the material damage cells in vitro. It is a common baseline screen, covered in detail in our guide to cytotoxicity testing and when it is required.
- Sensitization (ISO 10993-10): the potential to cause an allergic, immune-mediated skin response after repeated exposure, a particular concern for adhesives and some conductive materials.
- Irritation (ISO 10993-23): the potential to cause localized, non-immune skin reactions such as redness, particularly relevant under occlusion and friction.
- Chemical characterization (ISO 10993-18): identifying and, where needed, quantifying extractable and leachable substances, which then feeds a toxicological risk assessment under ISO 10993-17.
- Other endpoints: depending on the device, considerations such as systemic toxicity, material-mediated pyrogenicity, or sterilization residues (for example ethylene oxide residues under ISO 10993-7) may also be relevant.
Skin-contact materials and their considerations
Choosing materials for a wearable is a multidimensional problem. Biocompatibility is one axis, but it intersects with signal performance, mechanical flexibility, adhesion, moisture management, and manufacturability, and trade-offs between these properties are common.
Substrates and structural layers
Flexible substrates such as thermoplastic polyurethane (TPU) and polyurethane (PU) films, polyethylene terephthalate (PET), and nonwoven fabrics are widely used in wearable electrodes. Each differs in moisture vapor transmission, mechanical behavior, and surface chemistry. PU and TPU films generally offer good conformability and breathability, which supports comfort during extended wear. PET provides dimensional stability and suits reel-to-reel printing, but its lower breathability can contribute to skin occlusion over time. Additives, plasticizers, and processing aids in any polymer film are part of the formulation that should be understood.
Conductive layers and electrode materials
Silver and silver/silver chloride (Ag/AgCl) are established materials for biopotential electrodes. Their performance advantages are well known, and the biological question is not whether they are acceptable in general but whether the specific formulation, exposure, and wear conditions of a particular device present acceptable risk. Carbon-based inks offer an alternative with a different profile, typically at the cost of higher impedance. Binders, solvents, and additives in the ink contribute to the overall biological picture as much as the conductive particles themselves. For a deeper treatment, see our guide to biocompatible conductive materials for medical electrodes.
Adhesive and hydrogel systems
The adhesive or hydrogel layer is often the most skin-critical component of a wearable, because it sits in sustained, intimate contact with the skin and is the layer most affected by sweat, occlusion, and removal. Acrylic adhesives, hydrocolloids, silicone adhesives, and hydrogels each interact with skin differently. Adhesive-related reactions are among the most commonly reported skin issues with wearable devices, and some only emerge during extended wear studies rather than short bench tests.
Comparison of skin-contact material categories
| Material category | Typical role | Potential concerns | Evaluation considerations |
|---|---|---|---|
| PU / TPU films and nonwovens | Substrate, backing, skin-facing layer | Residual additives and processing aids; occlusion with low-breathability films | Formulation disclosure; extractables after processing; moisture vapor transmission relative to wear duration |
| PET films | Dimensionally stable printed substrate | Low breathability and occlusion on prolonged wear | Whether the film contacts skin directly; ventilation or design features; irritation under occlusion |
| Acrylic adhesives | Skin fixation | Residual monomers; sensitization in some users; skin stripping on removal | Sensitization and irritation evidence; wear trials; supplier changes handled through change control |
| Silicone adhesives | Gentle skin fixation, repeated use | Lower tack may limit wear time; additives and residues | Adhesion performance against wear duration; extractables; removal trauma |
| Hydrogels and hydrocolloids | Ionic coupling and adhesion for wet electrodes | Maceration under occlusion; sensitization to components; drying out | Electrical and biological evaluation together; formulation components; behavior with sweat and extended wear |
| Ag/AgCl and silver-based inks | Biopotential sensing layer | Silver ion release in sweat; localized reactions in sensitive users | Exposure level and skin-facing arrangement; wear duration; extractables from the finished assembly |
| Carbon-based inks | Alternative conductive layer | Binder and solvent residues; higher impedance affecting signal quality | Chemical characterization of the cured ink; trade-off with signal performance |
How wear conditions influence evaluation
Standardized tests do not reproduce everything a wearable experiences on a person. Prolonged wear, sweat, friction, occlusion, adhesive removal, and repeated application can all change both the exposure and the skin’s response.
- Sweat can mobilize ions and other extractable substances and alter electrode chemistry, affecting both signal quality and skin exposure.
- Occlusion traps moisture against the skin, which can soften the stratum corneum, increase irritation risk, and reduce adhesion.
- Friction and movement stress the adhesive interface and the skin surface, particularly in active users.
- Adhesive removal can cause mechanical skin trauma independent of chemical biocompatibility, and repeated removal at the same site compounds it.
- Repeated contact across days or weeks can change a device’s evaluation category through cumulative exposure.
These factors are one reason that bench testing alone may not capture adhesive-related adverse events, and why evaluation of wearables often benefits from realistic wear studies alongside laboratory endpoints. The right balance depends on the intended use and the risk analysis.
Supplier data, component evidence, and the finished device
Three kinds of evidence are easy to conflate, and distinguishing them is central to a sound evaluation.
- Supplier material information includes data sheets, certificates, and statements about a raw material or component. It is a valuable starting point for identifying formulation and hazards, but it describes the material as supplied, under the supplier’s conditions.
- Component-level evidence includes test results or characterization for an individual layer or subassembly. It can support the evaluation, but it does not automatically represent how that component behaves once combined and processed.
- Finished-device evaluation addresses the device as manufactured, in its final form, including interactions between materials, processing residues, packaging, and sterilization where applicable.
The device manufacturer, as the legal manufacturer responsible for the biological evaluation, must decide whether the available evidence adequately represents the finished device. Supplier documentation informs that decision but does not replace it.
How manufacturing and material changes affect biological risk
Biocompatibility is not determined solely by the raw materials in a bill of materials. Manufacturing can introduce or modify biological risk in ways that are easy to overlook.
Screen printing, flexographic printing, coating, and lamination involve solvents, curing agents, and process chemicals that may leave residues. Incomplete curing or drying can alter what a finished layer releases. Coatings and surface treatments can change the skin-facing chemistry of a component. Cleaning steps, handling, and packaging materials can also contribute substances. This is one reason chemical characterization under ISO 10993-18 is often approached on the finished device or a representative sample, so that extractables reflect the processed state rather than individual materials in isolation.
Sterilization is another process variable where relevant. Ethylene oxide can leave residues addressed under ISO 10993-7, and gamma irradiation can alter the properties of some polymers and adhesives. Where a device is supplied sterile, sterilization method and its effect on materials should be considered early, since testing an unsterilized prototype may not represent the final product.
Process consistency matters as well. A material stack evaluated at the prototype stage should be representative of what is produced at scale, and variation in cure levels, lamination pressure, or drying temperature can change extractable profiles. Material or supplier substitutions, even apparently minor ones such as a reformulated ink or a different adhesive source, should pass through change control that assesses biological implications and determines whether additional evidence is needed.
Material selection, signal performance, and manufacturability
Biological considerations rarely stand alone in a wearable electrode. A more breathable substrate may improve comfort but complicate printing registration. A highly conductive silver system may deliver excellent signal quality while raising questions about exposure under prolonged wear. A gentle adhesive may reduce skin trauma at removal but limit how long the device stays attached on active users, which in turn affects signal stability and data completeness. Hydrogel moisture content influences impedance and comfort, but also drying behavior and shelf life.
The practical implication is that biocompatibility, electrical performance, durability, comfort, and manufacturability should be developed together, with each material choice reviewed against all five. Decisions made on signal performance alone can create biological evaluation work later, and decisions made on biological conservatism alone can compromise performance or production yield. For applications such as ECG electrodes, these trade-offs are especially visible because skin contact, signal quality, and wear duration are tightly coupled.
Common pitfalls in wearable biocompatibility planning
- Adhesive sensitization: acrylate-based adhesives can contain residual monomers that act as contact allergens in a subset of users, and this risk is not reliably predicted by cytotoxicity screening alone.
- Silver exposure under extended wear: sweat accumulation and occlusion can change release behavior compared with short bench conditions.
- Substrate occlusion: impermeable films can lead to maceration and reduced adhesion over prolonged wear, which is partly a design and material selection issue.
- Reliance on supplier data alone: interactions that only occur in the combined, processed assembly can be missed without finished-device characterization.
- Late material changes: substitutions after evaluation is complete are a frequent source of delay when their biological impact has not been assessed.
Building biocompatibility into design and development
The most effective approach is to treat biological evaluation as a continuous risk management activity. A biological evaluation plan, in line with ISO 10993-1, should be drafted early. It records the device’s contact classification, identifies relevant biological endpoints, and sets out the evidence strategy and rationale, so that material decisions are made with regulatory consequences in view. Selecting materials with a documented history of use in comparable applications can help limit new evidence generation, although the relevance of that history must be justified for the specific device, duration, and population.
Design reviews should include biological checkpoints, and change control should flag biological implications of any material, supplier, or process change. As development moves toward scalable production, the links between material specification, process validation, and biological evaluation documentation should be explicit and traceable, so that reviewers can see that the evaluated device is representative of the manufactured one.
Responsibilities are worth stating plainly. The device manufacturer owns the biological evaluation, clinical validation, design controls, and regulatory approvals for the finished device. A contract development and manufacturing organization supports these by providing manufacturing capability, material and process information, and controlled production, but does not take over those responsibilities. Screentec is a Finnish ISO 13485 and ISO 9001-certified CDMO manufacturing customer-defined medical electrodes, wearable sensors, and specialized electronic components, and works within that division of responsibility. Where a project involves skin-contact materials, early dialogue about material options, process constraints, and documentation needs can help make the evaluation strategy practical to execute at scale.
If your team is weighing material options or assessing manufacturing feasibility for a custom skin-contact electrode assembly, discuss your material selection and manufacturing feasibility with Screentec.
References and further reading
- ISO 10993-1:2025, Biological evaluation of medical devices, Part 1: Evaluation and testing within a risk management process.
- ISO 10993-5, ISO 10993-7, ISO 10993-10, ISO 10993-17, ISO 10993-18, and ISO 10993-23, Biological evaluation of medical devices (individual parts as cited above).
- ISO 14971, Medical devices: Application of risk management to medical devices.
- U.S. Food and Drug Administration, guidance on the use of ISO 10993-1 for biological evaluation of medical devices within a risk management process.
- Regulation (EU) 2017/745 on medical devices (MDR).
Frequently Asked Questions
How do I know which ISO 10993 tests are required for my specific wearable device?
The required tests depend on three key factors: the nature of the body contact (surface skin, breached skin, or mucosal tissue), the duration of contact (short-term under 24 hours, prolonged up to 30 days, or permanent), and the materials used in the device. Start by drafting a Biological Evaluation Plan (BEP) as outlined in ISO 10993-1, which maps your device’s contact classification to the relevant biological endpoints. Working with a regulatory consultant or an experienced CDMO early in development can help you scope the testing matrix correctly and avoid over- or under-testing.
Can I rely on my material supplier's biocompatibility data instead of running my own tests?
Supplier data sheets and certificates can support your biological evaluation, but they cannot replace testing on your finished device assembly. ISO 10993-18 specifically requires extractables and leachables analysis on the device as manufactured, because interactions between materials — and the effects of your specific manufacturing processes such as curing, lamination, and sterilization — can introduce risks not captured by individual material data alone. Treat supplier documentation as a starting point for your chemical characterization, not a substitute for it.
What should I do if a skin adverse event is reported during a clinical wear trial?
First, systematically document the event: the wear duration, the skin site, the nature of the reaction (erythema, maceration, papules, etc.), and any user-specific factors such as known allergies or skin conditions. Then trace the event back to the most likely material candidates — adhesive systems and occlusive substrates are the most common culprits. Depending on the severity and frequency of events, you may need to initiate additional sensitization or irritation testing under ISO 10993-10 or ISO 10993-23, and potentially revisit your material selection before proceeding to larger studies.
How does switching to a new adhesive supplier mid-development affect our regulatory submission?
Even if the new adhesive appears chemically equivalent, a supplier change is considered a material change under ISO 10993 and typically triggers a biocompatibility impact assessment. In many cases, this will require repeating cytotoxicity and sensitization testing at a minimum, and potentially a full re-evaluation depending on how different the extractable profiles are. This is why establishing a robust change control process early — one that explicitly flags biocompatibility implications for any material or process substitution — is critical to protecting your development timeline and submission readiness.
Are there material combinations that are generally considered lower risk for extended-wear skin-contact devices?
Yes. Materials with a well-established history of safe use in equivalent applications — such as medical-grade polyurethane films, certain hydrocolloid adhesives, and Ag/AgCl electrode formulations validated for extended wear — can reduce your testing burden because ISO 10993-1 allows existing safety data to be leveraged. However, ‘lower risk’ is always relative to wear duration and patient population: a material suitable for a 24-hour patch may not be appropriate for a 7-day continuous wear device, particularly if the user population includes individuals with compromised or sensitive skin.
How does sterilization method selection affect biocompatibility, and how early should this decision be made?
Sterilization method selection should be made as early as possible in development — ideally before biocompatibility testing begins — because the sterilization process itself is part of the finished device’s biological risk profile. Ethylene oxide (EtO) can leave residues assessed under ISO 10993-7, while gamma irradiation can degrade certain polymers and adhesives, potentially altering their extractable profiles. If you test an unsterilized prototype and later introduce EtO sterilization, you may need to repeat portions of your biocompatibility evaluation. Aligning sterilization method, packaging, and material selection early prevents this costly sequencing problem.
What is the most common mistake development teams make when approaching biocompatibility for the first time?
The most common mistake is treating biocompatibility as a late-stage testing event rather than an ongoing design constraint. Teams that finalize material selections, manufacturing processes, and even clinical protocols before drafting a Biological Evaluation Plan often discover mid-development that their chosen materials require extensive testing, or that a process change has invalidated earlier test results. Starting with a BEP, selecting materials with regulatory history in mind, and building biocompatibility checkpoints into design reviews from feasibility onward significantly reduces the risk of costly late-stage redesign or regulatory delays.
This content was generated with the help of AI and it may contain mistakes
